Brigham & Womens Hospital, INC.

Brigham & Womens Hospital, INC. was paid $252.58M by Medicaid between Jan 2018 and Dec 2024, across 943 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 19% of everything it billed.

33Billing provider infoBRIGHAM & WOMENS HOSPITAL, INC.
BOSTON, MA 02115

33aNPI1790717650assigned 07/07/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$252.58M

24GClaims6,310,608

24DCodes billed943

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#6 of 66

Median peer was paid$29.11M

This provider vs. median8.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	913,441	$38.41M
2019	905,474	$35.73M
2020	789,315	$33.84M
2021	1,109,358	$45.60M
2022	1,129,645	$51.03M
2023	848,011	$27.95M
2024incomplete	615,364	$20.02M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	19%	372,174	313,004	$47.32M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	5.4%	148,331	125,230	$13.69M
J2350	Injection, ocrelizumab, 1 mg	3.4%	1,223	1,064	$8.60M
96361	Intravenous infusion, hydration; each additional hour	3.4%	23,167	20,604	$8.58M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	2.8%	49,924	45,721	$7.04M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	2.7%	22,689	19,131	$6.86M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	2.3%	39,413	36,170	$5.75M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	2.2%	278,056	219,901	$5.45M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	1.9%	25,930	23,352	$4.75M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.6%	73,136	64,424	$4.08M
G0378	Hospital observation service, per hour	1.5%	27,861	20,914	$3.84M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	1.5%	13,938	13,288	$3.70M

931 more codes

97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	1.3%	63,354	$3.37M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1.2%	3,136	$2.97M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	1.1%	5,014	$2.77M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.0%	21,107	$2.56M
90834	Psychotherapy session, about 45 minutes	1.0%	41,592	$2.56M
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	4,395	$2.50M
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	1,317	$2.39M
99214	Doctor's office visit, returning patient (more involved)	<1%	48,692	$2.20M
J2323	Injection, natalizumab, 1 mg	<1%	906	$2.13M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	13,974	$2.02M
59025	Fetal non-stress test	<1%	7,873	$1.94M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	7,944	$1.84M
J3490	Unclassified drugs	<1%	25,371	$1.66M
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	8,302	$1.61M
78815	Positron emission tomography (PET) for limited area imaging	<1%	1,941	$1.53M
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	17,106	$1.52M
J2357	Injection, omalizumab, 5 mg	<1%	2,622	$1.50M
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	1,462	$1.43M
70450	Computed tomography, head or brain; without contrast material	<1%	12,087	$1.37M
77063	Screening digital breast tomosynthesis, bilateral	<1%	19,800	$1.28M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	48,954	$1.24M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	48,981	$1.24M
99203	Doctor's office visit, new patient (routine)	<1%	8,684	$1.23M
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	2,085	$1.23M
S9485	Crisis intervention mental health services, per diem	<1%	2,012	$1.18M
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	8,319	$1.16M
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	11,008	$1.16M
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	1,014	$1.16M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	29,477	$1.15M
74183		<1%	4,811	$1.07M
76830	Ultrasound, transvaginal	<1%	10,807	$1.02M
71275	Computed tomographic angiography, chest, with contrast material	<1%	6,310	$1.01M
76801		<1%	9,783	$966K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	55,380	$875K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	6,648	$842K
76819	Fetal biophysical profile; without non-stress testing	<1%	11,453	$825K
96375	Therapeutic injection; each additional sequential IV push	<1%	24,132	$825K
71046	Radiologic examination, chest; 2 views	<1%	40,870	$801K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	190,955	$789K
96415		<1%	2,913	$782K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	2,388	$774K
97161		<1%	13,316	$754K
J0485	Injection, belatacept, 1 mg	<1%	2,192	$750K
93308		<1%	4,282	$728K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	5,435	$714K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	592	$700K
20610		<1%	5,868	$695K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	21,361	$693K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	8,308	$681K
77300		<1%	2,414	$661K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	3,419	$651K
D1110	Prophylaxis - adult	<1%	19,757	$646K
99215	Doctor's office visit, returning patient (complex)	<1%	5,922	$637K
72197		<1%	2,827	$636K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	4,852	$630K
76642		<1%	7,125	$623K
62323		<1%	1,730	$623K
84443	Thyroid stimulating hormone (TSH)	<1%	69,454	$617K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	38,740	$616K
93971		<1%	4,250	$615K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	1,023	$615K
D9450		<1%	48,440	$612K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	23,014	$610K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	25,885	$607K
86481		<1%	11,306	$604K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	4,905	$595K
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	9,953	$594K
87631		<1%	7,596	$593K
71250		<1%	9,691	$588K
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	10,549	$568K
92551		<1%	10,598	$565K
93970		<1%	3,155	$555K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	33,039	$553K
43235		<1%	885	$537K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	11,447	$535K
11102		<1%	1,282	$535K
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	10,638	$517K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	3,153	$507K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	<1%	824	$497K
36561		<1%	473	$493K
58300		<1%	1,897	$488K
83036	Hemoglobin; glycosylated (A1C)	<1%	98,871	$477K
70496		<1%	2,415	$476K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	9,336	$470K
76813		<1%	5,644	$468K
76536		<1%	5,086	$461K
J9312	Injection, rituximab, 10 mg	<1%	285	$454K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	37,438	$418K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	3,268	$411K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	4,264	$410K
11900		<1%	2,237	$404K
D2751	Crown - porcelain fused to predominantly base metal	<1%	871	$403K
72141		<1%	3,027	$401K
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	7,909	$388K
99201		<1%	3,224	$386K
90837	Psychotherapy session, about an hour	<1%	7,519	$385K
90651		<1%	3,620	$385K
90686		<1%	29,153	$379K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	53,313	$379K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	3,338	$377K
70544		<1%	2,512	$377K
77386		<1%	1,017	$375K
11104		<1%	762	$375K
81513		<1%	5,897	$375K
76770		<1%	2,910	$370K
D0120	Dental checkup, returning patient	<1%	21,929	$370K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	15,957	$369K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	18,743	$366K
77334		<1%	2,108	$365K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	4,525	$363K
93017		<1%	5,297	$359K
77080		<1%	7,084	$356K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	15,485	$355K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	16,219	$347K
64493		<1%	708	$341K
17110		<1%	2,070	$329K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	3,269	$327K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	5,783	$320K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	1,377	$315K
ATP15		<1%	40,826	$312K
83880		<1%	17,272	$311K
58100		<1%	1,132	$306K
82728		<1%	37,410	$306K
77301		<1%	945	$305K
83735		<1%	85,543	$302K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	7,393	$301K
78451		<1%	1,105	$298K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	72,973	$292K
57454		<1%	962	$292K
86780		<1%	28,168	$290K
84702		<1%	22,170	$289K
85027		<1%	81,529	$289K
D1120	Dental cleaning, child	<1%	5,663	$284K
73221		<1%	1,788	$283K
76820		<1%	7,296	$281K
ATP08		<1%	45,322	$260K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	8,054	$259K
58301		<1%	1,196	$258K
90715		<1%	11,742	$255K
97802		<1%	3,966	$251K
84484		<1%	27,790	$246K
86803		<1%	27,261	$246K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	3,915	$246K
D0274	Bitewings - four radiographic images	<1%	9,916	$245K
97803		<1%	4,181	$244K
94010		<1%	5,914	$237K
80048	Basic metabolic panel (calcium, ionized)	<1%	192,435	$235K
86850		<1%	32,968	$233K
20553		<1%	1,783	$230K
J2182	Injection, mepolizumab, 1 mg	<1%	271	$223K
77062		<1%	2,465	$221K
90832	Psychotherapy session, about 30 minutes	<1%	7,650	$221K
99173		<1%	11,741	$219K
87086	Culture, bacterial; quantitative colony count, urine	<1%	41,577	$218K
19083		<1%	283	$218K
71045	Radiologic examination, chest; single view	<1%	10,328	$216K
83970		<1%	14,120	$214K
82607		<1%	27,434	$209K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	19,882	$208K
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	22,149	$208K
97165		<1%	2,754	$206K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	<1%	68	$203K
0001A		<1%	6,659	$198K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	708	$197K
D2392	Resin-based composite - two surfaces, posterior, primary or permanent	<1%	3,652	$197K
ATP14		<1%	25,713	$180K
10005		<1%	572	$180K
0002A		<1%	5,736	$178K
D2391	Resin-based composite - one surface, posterior, primary or permanent	<1%	4,090	$172K
81025		<1%	31,040	$170K
72156		<1%	1,843	$170K
76882		<1%	1,809	$166K
77470		<1%	715	$164K
87632		<1%	1,605	$161K
77065	Tomosynthesis, mammo	<1%	3,802	$161K
70491		<1%	1,367	$156K
S0302	Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service)	<1%	17,763	$155K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	5,435	$153K
72158		<1%	1,303	$149K
77061		<1%	1,444	$148K
D7140	Extraction, erupted tooth or exposed root	<1%	3,161	$148K
87536		<1%	3,647	$147K
83690		<1%	32,110	$146K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	2,870	$146K
90750		<1%	2,288	$145K
93296		<1%	5,015	$142K
90791	Psychiatric diagnostic evaluation	<1%	2,049	$141K
73030		<1%	7,352	$139K
83605		<1%	17,916	$137K
73630		<1%	8,662	$136K
74246		<1%	909	$134K
83550		<1%	28,149	$133K
87481		<1%	5,839	$131K
88307		<1%	2,017	$127K
81001		<1%	72,039	$124K
86141		<1%	20,282	$123K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	2,463	$123K
10060		<1%	712	$123K
11100		<1%	507	$123K
D0140	Limited oral evaluation - problem focused	<1%	4,577	$122K
80076		<1%	93,281	$120K
85610		<1%	55,166	$118K
11056		<1%	1,377	$117K
73610		<1%	6,720	$116K
73564		<1%	7,047	$115K
D2150	Silver amalgam - two surfaces, primary or permanent	<1%	2,287	$113K
87340		<1%	14,956	$112K
88341		<1%	2,687	$111K
95886		<1%	590	$110K
77336		<1%	1,683	$110K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	135	$108K
86235		<1%	2,855	$108K
87077		<1%	18,854	$108K
97162		<1%	2,266	$107K
73502		<1%	6,392	$107K
17000		<1%	1,325	$106K
D1206	Topical application of fluoride varnish	<1%	3,941	$105K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	8,404	$104K
73130		<1%	6,683	$104K
83540		<1%	28,959	$102K
91065		<1%	633	$102K
72100		<1%	5,308	$101K
82784		<1%	11,079	$101K
82803		<1%	6,659	$100K
77290		<1%	189	$98K
82746		<1%	12,222	$97K
80050	General health panel	<1%	6,482	$96K
D0210	Intraoral - complete series of radiographic images	<1%	2,432	$96K
73562		<1%	6,439	$95K
78431		<1%	221	$95K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	6,538	$95K
86762		<1%	8,403	$95K
ATP03		<1%	31,074	$95K
88342		<1%	5,106	$94K
77002		<1%	2,488	$93K
86003		<1%	2,128	$90K
J7999	Compounded drug, not otherwise classified	<1%	7,711	$89K
86900		<1%	33,467	$89K
95117		<1%	4,185	$88K
72157		<1%	1,620	$88K
77295		<1%	171	$87K
0124A		<1%	3,420	$87K
72125	Computed tomography, cervical spine; without contrast material	<1%	3,384	$87K
92587		<1%	452	$85K
70498		<1%	1,829	$82K
84439		<1%	16,954	$82K
87070		<1%	14,744	$82K
ATP17		<1%	11,566	$82K
74178		<1%	595	$81K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	3,261	$81K
87088		<1%	15,016	$81K
91200		<1%	1,091	$81K
77338		<1%	1,075	$80K
94060		<1%	1,428	$78K
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	9,198	$77K
87081		<1%	19,633	$77K
11981		<1%	268	$76K
88185		<1%	384	$74K
86901		<1%	33,275	$74K
D1208	Topical application of fluoride, excluding varnish	<1%	2,554	$74K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	986	$73K
J1644	Injection, heparin sodium, per 1000 units	<1%	10,519	$72K
99385		<1%	1,007	$72K
ATP11		<1%	12,249	$72K
70486		<1%	1,126	$70K
ATP16		<1%	9,041	$70K
64615		<1%	369	$69K
G0105	Colorectal cancer screening; colonoscopy on individual at high risk	<1%	89	$68K
82570		<1%	33,537	$68K
76942		<1%	1,025	$67K
87040		<1%	6,087	$67K
80053	Comprehensive metabolic panel	<1%	83,591	$66K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	35,133	$66K
94726		<1%	1,610	$65K
J9310	Injection, rituximab, 100 mg	<1%	102	$64K
84146		<1%	5,237	$64K
74174		<1%	1,167	$64K
86787		<1%	6,410	$64K
82670		<1%	3,474	$62K
87799		<1%	6,622	$62K
0004A		<1%	2,630	$61K
88173		<1%	958	$61K
99381		<1%	795	$61K
84403		<1%	4,267	$60K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	5,833	$60K
62370		<1%	1,853	$60K
95885		<1%	320	$60K
87186		<1%	12,438	$59K
84153		<1%	6,323	$59K
96367		<1%	490	$59K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	31,193	$59K
86355		<1%	4,468	$59K
93321		<1%	714	$58K
J9999	Not otherwise classified, antineoplastic drugs	<1%	2,216	$57K
ATP18		<1%	8,099	$57K
83001		<1%	4,746	$56K
73110		<1%	3,549	$56K
77001		<1%	1,385	$56K
77066	Tomosynthesis, mammo	<1%	3,814	$56K
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	1,274	$56K
76775		<1%	684	$56K
87653		<1%	1,959	$55K
81003		<1%	38,128	$55K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	423	$55K
86706		<1%	8,159	$53K
87522	Neg quan hep c or qual rna	<1%	2,419	$52K
D2331		<1%	1,251	$52K
85730		<1%	9,912	$52K
83516		<1%	5,927	$51K
92610		<1%	403	$51K
82043		<1%	24,418	$50K
86140		<1%	19,273	$49K
90847	Family psychotherapy with the patient present, 50 minutes	<1%	540	$49K
84425		<1%	4,125	$48K
86360		<1%	2,670	$48K
D0150	Comprehensive oral evaluation - new or established patient	<1%	2,146	$48K
85379		<1%	7,283	$48K
J7050	Infusion, normal saline solution, 250 cc	<1%	23,852	$47K
D0220	Intraoral - periapical first radiographic image	<1%	4,729	$47K
73560		<1%	3,177	$47K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	3,023	$47K
11982		<1%	241	$47K
76937		<1%	1,944	$47K
73080		<1%	1,866	$46K
94729		<1%	2,331	$46K
90677		<1%	2,039	$46K
75574		<1%	390	$45K
93325		<1%	1,181	$45K
86160		<1%	3,974	$45K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	29,239	$45K
76857		<1%	708	$45K
64483		<1%	132	$44K
J1170	Injection, hydromorphone, up to 4 mg	<1%	14,303	$43K
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials	<1%	3,541	$43K
80061	Lipid panel	<1%	83,173	$43K
76604		<1%	538	$42K
99496		<1%	675	$42K
74018		<1%	1,328	$42K
72040		<1%	2,036	$41K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	17,787	$41K
85652		<1%	29,975	$40K
86038		<1%	6,114	$40K
90746		<1%	1,832	$39K
83520		<1%	4,358	$39K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	2,079	$39K
83021		<1%	2,320	$38K
86359		<1%	2,672	$38K
99386		<1%	651	$38K
86832		<1%	572	$38K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	938	$38K
80197		<1%	13,502	$37K
90472	Immunization administration, each additional vaccine (list separately)	<1%	12,911	$37K
D1351	Sealant - per tooth	<1%	1,015	$37K
83655		<1%	3,474	$37K
99205	Prolong outpt/office vis	<1%	226	$37K
0054A		<1%	1,830	$37K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	1,598	$36K
90732		<1%	2,613	$35K
84402		<1%	2,390	$35K
J2704	Injection, propofol, 10 mg	<1%	25,393	$34K
87497		<1%	3,786	$34K
87184		<1%	7,981	$34K
86357		<1%	2,245	$34K
0071A		<1%	786	$34K
94621		<1%	303	$33K
76870		<1%	332	$33K
ATP07		<1%	5,627	$33K
86833		<1%	541	$32K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	9,492	$32K
86334		<1%	3,859	$32K
86704		<1%	4,657	$32K
95816		<1%	156	$31K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	6,423	$31K
ATP09		<1%	5,569	$31K
J2791	Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu	<1%	138	$31K
72146		<1%	875	$31K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	312	$30K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	3,962	$30K
93975		<1%	321	$30K
86147		<1%	1,138	$30K
86765		<1%	3,473	$30K
D0272	Bitewings - two radiographic images	<1%	1,089	$30K
83002		<1%	2,428	$29K
72170		<1%	1,559	$29K
88304		<1%	1,614	$29K
70548		<1%	176	$28K
73552		<1%	1,340	$28K
86225		<1%	4,269	$28K
86769		<1%	1,282	$27K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,705	$27K
93880		<1%	435	$26K
20550		<1%	173	$26K
73700		<1%	535	$25K
84590		<1%	3,874	$25K
88360		<1%	478	$25K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	181	$25K
84480		<1%	2,982	$25K
90662		<1%	8,001	$25K
87338		<1%	2,823	$24K
20552		<1%	193	$24K
91320		<1%	1,725	$24K
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)	<1%	62	$24K
90670		<1%	5,734	$24K
99443		<1%	4,447	$24K
83020		<1%	2,244	$23K
D2160		<1%	495	$23K
75561		<1%	116	$23K
84156		<1%	14,463	$23K
49083		<1%	73	$23K
82950		<1%	5,407	$22K
73140		<1%	964	$22K
86618		<1%	2,229	$22K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	80	$22K
90480		<1%	2,259	$22K
90714		<1%	891	$22K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	42,619	$21K
72070		<1%	738	$21K
99495		<1%	544	$21K
71271		<1%	881	$21K
0072A		<1%	461	$21K
87517		<1%	1,079	$21K
86677		<1%	1,988	$21K
D2140		<1%	570	$20K
82330		<1%	3,107	$20K
Q3014	Telehealth originating site facility fee	<1%	13,432	$20K
ATP10		<1%	3,844	$20K
A9585	Injection, gadobutrol, 0.1 ml	<1%	26,979	$20K
82533		<1%	2,301	$19K
D2393	Resin-based composite - three surfaces, posterior, primary or permanent	<1%	469	$19K
19081		<1%	28	$19K
99397		<1%	927	$19K
86923		<1%	1,283	$19K
73590		<1%	2,077	$19K
96409		<1%	36	$19K
72131		<1%	635	$19K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	11,642	$18K
J0690	Injection, cefazolin sodium, 500 mg	<1%	9,670	$18K
96900		<1%	433	$18K
84165		<1%	4,533	$18K
ATP23		<1%	1,992	$18K
87625		<1%	992	$18K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	914	$18K
87102		<1%	3,415	$18K
80179		<1%	1,425	$17K
64494		<1%	563	$17K
88108		<1%	661	$17K
J1756	Injection, iron sucrose, 1 mg	<1%	409	$17K
86708		<1%	2,581	$16K
93976		<1%	174	$16K
84100		<1%	35,003	$16K
86200		<1%	2,357	$16K
94664		<1%	487	$16K
86735		<1%	1,926	$15K
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	4,845	$15K
82088		<1%	778	$15K
82105		<1%	1,879	$15K
95004	Percutaneous tests with allergenic extracts, immediate type reaction	<1%	169	$15K
73060		<1%	427	$14K
82785		<1%	1,637	$14K
99188		<1%	1,139	$14K
86376		<1%	1,472	$14K
82024		<1%	664	$14K
82627		<1%	849	$14K
90691		<1%	590	$13K
29581		<1%	142	$13K
87529		<1%	569	$13K
88184		<1%	493	$13K
87210		<1%	4,951	$13K
90696		<1%	866	$13K
83993		<1%	1,188	$13K
0031A		<1%	405	$13K
86146		<1%	814	$13K
86255		<1%	1,740	$13K
81229		<1%	13	$12K
70543		<1%	40	$12K
85045		<1%	6,468	$12K
ATP04		<1%	2,197	$12K
90734		<1%	2,468	$12K
J0248	Injection, remdesivir, 1 mg	<1%	31	$12K
82610		<1%	3,135	$12K
64450		<1%	58	$12K
87252		<1%	595	$11K
95076		<1%	12	$11K
86431		<1%	3,769	$11K
80299		<1%	982	$11K
G0008	Administration of influenza virus vaccine	<1%	11,182	$11K
J3370	Injection, vancomycin hcl, 500 mg	<1%	2,872	$11K
96376		<1%	7,136	$11K
90461		<1%	3,383	$11K
87106		<1%	1,468	$11K
36415	Collection of venous blood by venipuncture	<1%	131,369	$11K
87400		<1%	747	$11K
J1726	Injection, hydroxyprogesterone caproate, (makena), 10 mg	<1%	217	$11K
88112		<1%	370	$11K
C1769	Guide wire	<1%	2,760	$11K
93923		<1%	186	$11K
77081		<1%	448	$11K
11901		<1%	70	$11K
11721		<1%	459	$11K
0051A		<1%	287	$10K
80143		<1%	1,321	$10K
87205		<1%	4,452	$10K
87177		<1%	2,044	$10K
84134		<1%	1,805	$10K
83921		<1%	1,178	$10K
80164		<1%	1,836	$10K
87046		<1%	1,640	$10K
81450		<1%	111	$10K
82550		<1%	8,970	$10K
0081A		<1%	224	$10K
87209		<1%	1,043	$9K
86800		<1%	1,105	$9K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	5,274	$9K
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	<1%	2,293	$9K
ATP12		<1%	1,449	$9K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	454	$9K
D0330	Panoramic radiographic image	<1%	227	$9K
82274		<1%	1,208	$9K
84244		<1%	838	$9K
87045		<1%	1,593	$8K
73523		<1%	741	$8K
88313		<1%	361	$8K
J3262	Injection, tocilizumab, 1 mg	<1%	53	$8K
90716		<1%	1,509	$8K
D2330		<1%	227	$8K
77332		<1%	79	$8K
82565		<1%	9,137	$8K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	7,192	$8K
83721		<1%	2,379	$8K
92083		<1%	214	$8K
97116		<1%	351	$8K
80175		<1%	1,747	$8K
82951		<1%	658	$8K
95913		<1%	88	$8K
90792	Psychiatric diagnostic evaluation with medical services	<1%	887	$8K
87324		<1%	1,433	$7K
80177		<1%	1,334	$7K
64650		<1%	24	$7K
J7300	Intrauterine copper contraceptive (paragard)	<1%	129	$7K
0154A		<1%	211	$7K
20605		<1%	53	$7K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	4,453	$7K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	2,858	$7K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	9,054	$7K
83615		<1%	6,991	$7K
76376		<1%	646	$7K
78264		<1%	38	$7K
73720		<1%	31	$7K
84445		<1%	181	$7K
ATP05		<1%	1,088	$7K
0082A		<1%	147	$7K
90707		<1%	1,685	$7K
J3489	Injection, zoledronic acid, 1 mg	<1%	205	$7K
72195		<1%	53	$6K
85007		<1%	3,598	$6K
93299		<1%	169	$6K
93298		<1%	288	$6K
84144		<1%	421	$6K
86039		<1%	1,021	$6K
94618		<1%	161	$6K
84550		<1%	8,958	$6K
82010		<1%	1,185	$6K
D0145	Oral evaluation for a patient under three years of age	<1%	227	$6K
G0127	Trimming of dystrophic nails, any number	<1%	2,968	$6K
85613		<1%	1,018	$6K
74221		<1%	51	$6K
90656		<1%	625	$6K
84630		<1%	631	$6K
86694		<1%	538	$6K
58558		<1%	13	$6K
ATP02		<1%	1,445	$6K
J2060	Injection, lorazepam, 2 mg	<1%	4,097	$6K
85597		<1%	535	$5K
90632		<1%	314	$5K
86665		<1%	318	$5K
85018		<1%	2,744	$5K
84432		<1%	643	$5K
69209		<1%	43	$5K
87641		<1%	206	$5K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	19	$5K
S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	269	$5K
C7900	Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 15-29 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service	<1%	731	$5K
84681		<1%	462	$5K
86828		<1%	459	$5K
83718		<1%	798	$5K
87116		<1%	868	$5K
93356		<1%	1,471	$5K
87075		<1%	1,023	$5K
0064A		<1%	217	$4K
0012A		<1%	207	$4K
57456		<1%	14	$4K
86580		<1%	628	$4K
85384		<1%	773	$4K
10061		<1%	28	$4K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	654	$4K
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	3,257	$4K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	1,164	$4K
85014		<1%	2,032	$4K
97166		<1%	51	$4K
88312		<1%	521	$4K
86162		<1%	390	$4K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	28,218	$4K
83519		<1%	441	$4K
84305		<1%	357	$4K
83525		<1%	567	$4K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	1,023	$4K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	95	$4K
86352		<1%	105	$4K
99153	Mod sedat endo service >5yrs	<1%	7,868	$4K
99204	Doctor's office visit, new patient (more involved)	<1%	39	$4K
C7901	Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service	<1%	2,951	$4K
80074		<1%	106	$4K
81206		<1%	260	$4K
73090		<1%	326	$4K
86356		<1%	439	$4K
0011A		<1%	211	$4K
89051		<1%	1,192	$4K
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	512	$3K
86644		<1%	433	$3K
96127		<1%	336	$3K
0003A		<1%	181	$3K
86870		<1%	240	$3K
84132		<1%	4,253	$3K
ATP19		<1%	471	$3K
88346		<1%	152	$3K
0074A		<1%	80	$3K
90682		<1%	170	$3K
ATP13		<1%	376	$3K
88350		<1%	61	$3K
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	<1%	14,436	$3K
82947		<1%	2,832	$3K
87015		<1%	848	$3K
D0270		<1%	374	$3K
0052A		<1%	62	$3K
86682		<1%	436	$3K
80178		<1%	920	$3K
83498		<1%	130	$3K
D0230	Intraoral - periapical each additional radiographic image	<1%	446	$3K
87206		<1%	882	$2K
82150		<1%	577	$2K
77370		<1%	19	$2K
99152		<1%	5,751	$2K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	2,062	$2K
72110		<1%	192	$2K
J1020	Injection, methylprednisolone acetate, 20 mg	<1%	2,784	$2K
99442		<1%	884	$2K
89343		<1%	65	$2K
93225		<1%	52	$2K
83930		<1%	707	$2K
82390		<1%	363	$2K
84300		<1%	1,107	$2K
82952		<1%	657	$2K
98940		<1%	368	$2K
87150		<1%	186	$2K
J7030	Infusion, normal saline solution , 1000 cc	<1%	1,243	$2K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	1,421	$2K
84163		<1%	133	$2K
93280		<1%	259	$2K
90620		<1%	38	$2K
82140		<1%	306	$2K
77012		<1%	208	$2K
17003		<1%	420	$2K
86593		<1%	724	$2K
82725		<1%	189	$2K
83835		<1%	187	$2K
84154		<1%	268	$2K
36430		<1%	12	$2K
84270		<1%	146	$2K
84460		<1%	6,892	$2K
86941		<1%	205	$2K
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	1,621	$2K
82248		<1%	4,742	$2K
83010		<1%	348	$2K
73718		<1%	12	$2K
82525		<1%	169	$2K
73218		<1%	14	$2K
87563		<1%	69	$2K
94727		<1%	42	$2K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	3,577	$2K
82465		<1%	910	$2K
D2335		<1%	30	$2K
82787		<1%	112	$2K
82103		<1%	221	$2K
82085		<1%	291	$2K
D2332		<1%	27	$2K
86705		<1%	211	$1K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	541	$1K
86341		<1%	123	$1K
D9110		<1%	63	$1K
93350		<1%	79	$1K
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	3,491	$1K
95018		<1%	12	$1K
95911		<1%	12	$1K
D7111		<1%	18	$1K
92133		<1%	71	$1K
82310		<1%	1,254	$1K
90474		<1%	1,972	$1K
86805		<1%	14	$1K
G0009	Administration of pneumococcal vaccine	<1%	2,584	$1K
J0897	Injection, denosumab, 1 mg	<1%	15	$1K
95250		<1%	83	$1K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	27	$1K
J1630	Injection, haloperidol, up to 5 mg	<1%	1,021	$1K
87640		<1%	206	$1K
72050		<1%	97	$1K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,511	$1K
88348		<1%	39	$1K
84207		<1%	64	$1K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	17	$1K
86317		<1%	96	$984.13
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	573	$980.10
95024		<1%	37	$972.43
83935		<1%	397	$959.13
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	2,627	$957.91
11103		<1%	12	$937.60
90688		<1%	61	$916.27
82962		<1%	10,201	$909.95
73200		<1%	26	$886.15
86664		<1%	100	$821.89
90678		<1%	46	$821.64
82542		<1%	83	$814.25
82731		<1%	15	$797.04
87505		<1%	16	$792.05
94761		<1%	319	$785.50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	314	$759.43
90636		<1%	12	$744.45
87329		<1%	105	$739.46
84450		<1%	4,116	$738.97
93926		<1%	13	$732.47
82270		<1%	363	$732.12
83695		<1%	154	$718.11
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	17	$679.68
G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	<1%	561	$679.65
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	1,007	$646.36
83521		<1%	930	$642.95
84446		<1%	86	$630.62
82247		<1%	1,093	$618.79
11720		<1%	15	$615.92
84166		<1%	68	$605.45
90836		<1%	253	$597.94
88302		<1%	54	$572.90
80069		<1%	2,642	$569.71
87181		<1%	206	$563.72
99493		<1%	29	$559.18
83090		<1%	58	$551.88
97750		<1%	62	$538.15
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	863	$533.47
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	17	$508.32
82985		<1%	56	$481.25
74220		<1%	27	$470.86
84080		<1%	84	$466.34
84466		<1%	50	$464.94
0053A		<1%	14	$458.70
82378		<1%	50	$454.20
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	2,428	$452.39
84145		<1%	2,615	$438.51
90674		<1%	13	$435.24
74175		<1%	42	$432.22
S0028	Injection, famotidine, 20 mg	<1%	462	$416.82
85347		<1%	132	$388.09
73000		<1%	14	$380.35
0034A		<1%	15	$366.96
84436		<1%	142	$341.85
85240		<1%	26	$326.60
J1836	Injection, metronidazole, 10 mg	<1%	268	$317.78
ATP06		<1%	78	$315.12
96158		<1%	19	$312.97
71100		<1%	29	$312.22
86645		<1%	27	$295.80
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	5,779	$290.27
99383		<1%	15	$289.13
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	407	$279.98
82040		<1%	1,811	$279.55
62368		<1%	14	$278.30
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	120	$275.06
84295		<1%	1,297	$266.04
93283		<1%	12	$254.22
82166		<1%	18	$238.42
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	29	$231.88
0013A		<1%	12	$229.35
82977		<1%	887	$224.80
86308		<1%	58	$221.32
99177		<1%	128	$218.05
84478		<1%	940	$205.15
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	114	$199.25
87147		<1%	50	$197.58
72128		<1%	26	$196.75
86663		<1%	29	$177.15
84075		<1%	890	$153.12
73503		<1%	48	$150.82
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	<1%	5,733	$149.41
82340		<1%	52	$148.50
90633		<1%	3,055	$139.50
96368		<1%	16	$134.50
86304		<1%	13	$132.93
80183		<1%	26	$130.19
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	1,700	$118.15
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	19	$115.16
74019		<1%	27	$114.10
82180		<1%	28	$106.67
87299		<1%	26	$106.29
82131		<1%	12	$104.34
86709		<1%	12	$102.70
96040		<1%	1,635	$102.00
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	118	$99.03
80235		<1%	40	$95.64
93786		<1%	31	$93.52
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	<1%	307	$85.06
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	2,478	$79.19
80201		<1%	15	$73.57
J1940	Injection, furosemide, up to 20 mg	<1%	747	$66.01
J0610	Injection, calcium gluconate (fresenius kabi), per 10 ml	<1%	417	$63.79
J1956	Injection, levofloxacin, 250 mg	<1%	30	$62.14
80156		<1%	13	$60.12
G0101	Cervical or vaginal cancer screening; pelvic and clinical breast examination	<1%	164	$57.26
G0442	Annual alcohol misuse screening, 5 to 15 minutes	<1%	49	$55.10
99494		<1%	15	$55.03
J0670	Injection, mepivacaine hydrochloride, per 10 ml	<1%	306	$48.65
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	752	$47.43
J8540	Dexamethasone, oral, 0.25 mg	<1%	325	$45.76
89060		<1%	14	$39.12
80158		<1%	12	$37.24
51701		<1%	57	$35.97
90713		<1%	171	$35.37
90710		<1%	1,153	$32.65
86036		<1%	476	$29.85
87185		<1%	14	$29.34
36410		<1%	326	$28.98
85598		<1%	13	$28.86
84520		<1%	1,644	$26.19
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	652	$24.56
95991		<1%	17	$18.20
86381		<1%	154	$17.82
G0444	Annual depression screening, 5 to 15 minutes	<1%	12	$8.32
J0613	Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg	<1%	111	$6.96
J1171	Injection, hydromorphone, 0.1 mg	<1%	135	$4.35
90685		<1%	301	$2.36
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	<1%	659	$1.59
S0119	Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code)	<1%	1,747	$1.47
Q9965	Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml	<1%	958	$0.39
G0010	Administration of hepatitis b vaccine	<1%	101	$0.09
90749		<1%	14	$0.05
90698		0%	2,859	$0.00
J3480	Injection, potassium chloride, per 2 meq	0%	418	$0.00
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	0%	3,449	$0.00
90744		0%	1,872	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	222	$0.00
82435		0%	552	$0.00
J1010	Injection, methylprednisolone acetate, 1 mg	0%	474	$0.00
L4360	Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	349	$0.00
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	0%	165	$0.00
90680		0%	3,180	$0.00
D1330		0%	387	$0.00
91301		0%	138	$0.00
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	0%	159	$0.00
J2785	Injection, regadenoson, 0.1 mg	0%	453	$0.00
90697		0%	110	$0.00
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	0%	213	$0.00
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	116	$0.00
88300		0%	12	$0.00
81596		0%	268	$0.00
91303		0%	283	$0.00
95012		0%	314	$0.00
93246		0%	39	$0.00
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	207	$0.00
90723		0%	336	$0.00
96139		0%	13	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	40	$0.00
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	0%	96	$0.00
89322		0%	25	$0.00
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	0%	12	$0.00
87484		0%	14	$0.00
J1790	Injection, droperidol, up to 5 mg	0%	68	$0.00
J0611	Injection, calcium gluconate (wg critical care), per 10 ml	0%	52	$0.00
J0360	Injection, hydralazine hcl, up to 20 mg	0%	54	$0.00
96132		0%	28	$0.00
93788		0%	31	$0.00
L1810	Knee orthosis, elastic with joints, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	13	$0.00
J3411	Injection, thiamine hcl, 100 mg	0%	17	$0.00
G8986	Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting	0%	12	$0.00
J0461	Injection, atropine sulfate, 0.01 mg	0%	43	$0.00
81370		0%	13	$0.00
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	0%	14	$0.00
D2750		0%	19	$0.00
88331		0%	14	$0.00
C1819	Surgical tissue localization and excision device (implantable)	0%	13	$0.00
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens	0%	18	$0.00
95874		0%	13	$0.00
90648		0%	1,518	$0.00
L3908	Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf	0%	789	$0.00
C1758	Catheter, ureteral	0%	40	$0.00
L0626	Lumbar orthosis, sagittal control, with rigid posterior panel(s), posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	284	$0.00
91300		0%	10,320	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	1,048	$0.00
90700		0%	1,063	$0.00
A9577	Injection, gadobenate dimeglumine (multihance), per ml	0%	27	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	1,152	$0.00
80348		0%	478	$0.00
86015		0%	139	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	309	$0.00
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	0%	7,160	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	363	$0.00
80361		0%	403	$0.00
J1596	Injection, glycopyrrolate, 0.1 mg	0%	199	$0.00
Q9956	Injection, octafluoropropane microspheres, per ml	0%	767	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	283	$0.00
91312		0%	867	$0.00
90672		0%	76	$0.00
C1729	Catheter, drainage	0%	214	$0.00
96133		0%	28	$0.00
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	0%	105	$0.00
C9113	Injection, pantoprazole sodium, per vial	0%	306	$0.00
80346		0%	480	$0.00
L1820	Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	16	$0.00
78434		0%	120	$0.00
80362		0%	403	$0.00
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	0%	92	$0.00
D0160		0%	16	$0.00
84155		0%	29	$0.00
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	0%	24	$0.00
A9575	Injection, gadoterate meglumine, 0.1 ml	0%	62	$0.00
80365		0%	478	$0.00
G8989	Self care functional limitation, discharge status, at discharge from therapy or to end reporting	0%	13	$0.00
96136		0%	12	$0.00
0121A		0%	16	$0.00
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	0%	18	$0.00
A9526	Nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries	0%	12	$0.00
11101		0%	12	$0.00
C1788	Port, indwelling (implantable)	0%	12	$0.00
96138		0%	13	$0.00
86008		0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMORASH, DANIEL (CFO)

Same official

Other billing entities under MORASH, DANIEL

Full network →

Provider	Location	Paid
Brigham & Womens Physicians Organization INC	Boston, MA	$43.38M
Brigham & Women's Physicians Organization INC	Milford, MA	$755.61

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.